Boston Scientific Corp Stock Revenue
| BSX Stock | USD 91.50 1.33 1.47% |
Boston Scientific Corp fundamentals help investors to digest information that contributes to Boston Scientific's financial success or failures. It also enables traders to predict the movement of Boston Stock. The fundamental analysis module provides a way to measure Boston Scientific's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Boston Scientific stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 14.2 B | 15 B |
Boston | Revenue |
Boston Scientific Corp Company Revenue Analysis
Boston Scientific's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Boston Scientific Revenue | 14.24 B |
Most of Boston Scientific's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boston Scientific Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Boston
Projected quarterly revenue analysis of Boston Scientific Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Boston Scientific match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Boston Scientific's stock price.
Boston Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Boston Scientific is extremely important. It helps to project a fair market value of Boston Stock properly, considering its historical fundamentals such as Revenue. Since Boston Scientific's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boston Scientific's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boston Scientific's interrelated accounts and indicators.
| -0.42 | -0.41 | -0.21 | -0.44 | -0.3 | ||
| -0.42 | 0.99 | 0.73 | 1.0 | 0.07 | ||
| -0.41 | 0.99 | 0.7 | 0.98 | 0.02 | ||
| -0.21 | 0.73 | 0.7 | 0.71 | 0.21 | ||
| -0.44 | 1.0 | 0.98 | 0.71 | 0.08 | ||
| -0.3 | 0.07 | 0.02 | 0.21 | 0.08 |
Click cells to compare fundamentals
Boston Revenue Historical Pattern
Today, most investors in Boston Scientific Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Boston Scientific's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Boston Scientific revenue as a starting point in their analysis.
Boston Scientific Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Boston Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Boston Scientific Corp reported 14.24 B of revenue. This is 86.71% higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 50.93% lower than that of the firm.
Boston Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boston Scientific's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boston Scientific could also be used in its relative valuation, which is a method of valuing Boston Scientific by comparing valuation metrics of similar companies.Boston Scientific is currently under evaluation in revenue category among its peers.
Boston Scientific ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boston Scientific's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boston Scientific's managers, analysts, and investors.Environmental | Governance | Social |
Boston Scientific Institutional Holders
Institutional Holdings refers to the ownership stake in Boston Scientific that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Boston Scientific's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Boston Scientific's value.| Shares | Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main | 2024-06-30 | 22.3 M | Capital World Investors | 2024-09-30 | 21.7 M | Bollard Group Llc | 2024-06-30 | 21.7 M | Hhg Plc | 2024-06-30 | 18.3 M | Norges Bank | 2024-06-30 | 17.9 M | Franklin Resources Inc | 2024-06-30 | 17.2 M | Amundi | 2024-06-30 | 15.4 M | Bank Of New York Mellon Corp | 2024-06-30 | 14.8 M | Artisan Partners Limited Partnership | 2024-06-30 | 14.7 M | Fmr Inc | 2024-09-30 | 135.2 M | Vanguard Group Inc | 2024-09-30 | 131.3 M |
Boston Fundamentals
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 141.65 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 92.35 % | ||||
| Number Of Shares Shorted | 12.91 M | ||||
| Price To Earning | 107.05 X | ||||
| Price To Book | 6.42 X | ||||
| Price To Sales | 8.48 X | ||||
| Revenue | 14.24 B | ||||
| Gross Profit | 8.68 B | ||||
| EBITDA | 3.45 B | ||||
| Net Income | 1.59 B | ||||
| Cash And Equivalents | 928 M | ||||
| Cash Per Share | 0.24 X | ||||
| Total Debt | 9.49 B | ||||
| Debt To Equity | 0.51 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | 14.05 X | ||||
| Cash Flow From Operations | 2.5 B | ||||
| Short Ratio | 1.91 X | ||||
| Earnings Per Share | 1.21 X | ||||
| Price To Earnings To Growth | 1.63 X | ||||
| Target Price | 97.0 | ||||
| Number Of Employees | 48 K | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 134.86 B | ||||
| Total Asset | 35.14 B | ||||
| Retained Earnings | 819 M | ||||
| Working Capital | 1.58 B | ||||
| Current Asset | 1.21 B | ||||
| Current Liabilities | 923 M | ||||
| Net Asset | 35.14 B |
About Boston Scientific Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Boston Scientific Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boston Scientific using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boston Scientific Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.